Ozenoxacin
- Generic Name
- Ozenoxacin
- Brand Names
- Ozanex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21N3O3
- CAS Number
- 245765-41-7
- Unique Ingredient Identifier
- V0LH498RFO
- Background
To date, ozenoxacin has been used in trials studying the treatment of impetigo.
As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone that has demonstrated safe and effective therapy in both the adult and pediatric population.
- Indication
Ozenoxacin cream is indicated for the topical treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients aged 2 months of age and older .
- Associated Conditions
- Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 412
- Registration Number
- NCT02090764
- Locations
- 🇵🇷
Caparra Internal Medicine Center, Rio Grande, Puerto Rico
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
- Conditions
- Impetigo
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 465
- Registration Number
- NCT01397461
- Locations
- 🇩🇪
Georg Popp, Augsburg, Germany
🇩🇪Diamant Thaci, Frankfurt/Main, Germany
🇿🇦Yacoob Vahed, Welkom, South Africa
Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions
- Conditions
- Secondarily Infected Traumatic Lesions
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Ferrer Internacional S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT01005771
- Locations
- 🇩🇪
Dermatologische Praxis, Mahlow, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.